Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities
Net loss	$ (47,497)	$ (34,541)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	7,342	3,709
Depreciation on property and equipment	24	10
Foreign currency translation adjustments	(206)	(344)
Loss on disposal of property and equipment	0	14
Noncash lease expense	431
Write-off of deferred offering costs	0	1,398
Other	0	(40)
Changes in operating assets and liabilities:
Prepaid expenses	(394)	2,120
Income tax receivable	(4)	44
Value-added tax receivable	3,009	(8)
Accounts payable	4,737	963
Accrued expenses	(5,166)	664
Due to Roivant Sciences Ltd.	(149)	111
Income tax payable	0	11
Operating lease liabilities	(143)
Net cash used in operating activities	(38,016)	(25,889)
Cash flows from investing activities
Purchase of property and equipment	(86)	(8)
Net cash used in investing activities	(86)	(8)
Cash flows from financing activities
Capital contributions	217	551
Proceeds from stock options exercised	182	0
Payment of deferred offering costs	(975)	(554)
Proceeds from notes payable	0	35,000
Repayment of convertible promissory notes payable	0	(2,500)
Net cash provided by financing activities	381,903	37,904
Net change in cash	343,801	12,007
Cash – beginning of period	100,571	6,985
Cash – end of period	444,372	18,992
Non-cash operating activity
Operating lease right-of-use assets obtained and exchanged for operating lease liabilities	3,924	0
Non-cash investing activity
Purchase of property and equipment in accounts payable	0	6
Non-cash financing activity
Deferred offering costs in accrued expenses	261	1,178
Supplemental disclosure of cash paid:
Income taxes	92	0
Underwritten Public Offering
Cash flows from financing activities
Proceeds from issuance of common stock	319,783	0
Warrant Redemption
Cash flows from financing activities
Proceeds from issuance of common stock	65,752	0
Roivant Sciences Ltd. (RSL)
Cash flows from financing activities
Proceeds from notes payable	0	7,907
Repayment of note payable to Roivant Sciences Ltd.	$ (3,056)	$ (2,500)